Mavacamten Controlled Hypertrophic Cardiomyopathy for >1 Year

Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.
Medscape Medical News

source https://www.medscape.com/viewarticle/971493?src=rss

Comments

Post a Comment

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Rheumatoid arthritis increased the risk for lung cancer, and this risk was threefold higher in patients with rheumatoid arthritis–associated interstitial lung disease. Medscape Medical News source https://www.medscape.com/viewarticle/rheumatoid-arthritis-and-ra-associated-interstitial-lung-2024a1000epm?src=rss
Read more

Heart Failure Care Outside of ICU Can Lower Cost

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU is more cost effective, among other advantages. Medscape Medical News source https://www.medscape.com/viewarticle/heart-failure-care-outside-icu-can-lower-cost-2025a10006iy?src=rss
Read more